SCHEMBL3528077

SCHEMBL3528077

CC(C)(OCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2c(c1)OCCO2)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 14/20 0.59
PPARD Q03181 10/20 0.59
PPARA Q07869 9/20 0.59
SLC16A3 O15427 2/20 0.46
SLC16A1 P53985 2/20 0.46
PKM P14618 1/20 0.43
PKLR P30613 1/20 0.43
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CREBBP Q92793 1/20 0.41
ACLY P53396 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3526453 0.95 PPARG (0.66) PPARGPPARDPPARASLC16A3SLC16A1
SCHEMBL3520659 0.91 PPARG (0.55) PPARGPPARDPPARAPKMPKLR
SCHEMBL3524214 0.91 PPARG (0.52) PPARGPPARDPPARASLC16A3SLC16A1
SCHEMBL3522775 0.88 PPARG (0.62) PPARGPPARDPPARAALDH1A1HTT
SCHEMBL3527486 0.88 PPARG (0.49) PPARGPPARDPPARAPKMPKLR
SCHEMBL3523178 0.86 PPARG (0.62) PPARGPPARDPPARALMNAMAPT
SCHEMBL3528468 0.86 PPARG (0.43) PPARGPPARDPPARASLC16A3SLC16A1
SCHEMBL3529125 0.84 PPARG (0.59) PPARGPPARDPPARAPKMPKLR
SCHEMBL3522637 0.84 PPARG (0.69) PPARGPPARDPPARAACLY
SCHEMBL3522573 0.82 PPARG (0.51) PPARGPPARDPPARASLC16A3SLC16A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP PPARG 1018/4885PPARD 677/4885PPARA 847/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG PPARG 3/4885PPARD 4/4885PPARA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.